de Magalhães interview: “Still lots of work to do”

Professor João Pedro de Magalhães on different areas of Longevity.

Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro de Magalhães, PhD, Professor at the Institute of Ageing and Chronic Disease at the University of Liverpool.

Longevity.Technology: João Pedro is a scientist and futurist whose Human Ageing Genomic Resources database is an important tool for studying the genetics of human aging. With his eye on the spread of Longevity areas before him, we asked João Pedro which areas warrant more attention.

João Pedro de Magalhães: I think the mechanisms of aging seems to have disappeared from the radar a bit. There is a lot of focus on Longevity manipulations and interventions, but I think the field has kind of focussed less on understanding the process of aging.

Longevity.Technology: What about education on Longevity for investors?

João Pedro de Magalhães: I still think there’s a lot we need to do in terms of educating investors, yes, although of course there are now more investors and some of them are more knowledgeable about Longevity and aging. Nonetheless, still lots of work to do and your efforts in this are very much appreciated.

Longevity.Technology: Which areas will always underpin Longevity, do you think? Might changes be coming?

João Pedro de Magalhães: Immunotherapy is very much focused on cancer, and I don’t think it’s going to go away any time soon. Senolytics are fashionable now, but they weren’t sometime ago, so they may come and go, hard to say. And there will likely be other pharmacological interventions that will be of interest and may become more popular down the line. I think genetherapy will grow in popularity, actually, it’s still not very mainstream.

Check out our earlier interview with Advisory Panel member and LyGenesis CEO Michael Hufford.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...